Answers are grounded in this paper and cite their sources.
Cancer genomic medicine (CGM) encompasses the integration of tumor genomic information into clinical decision-making. In Japan, comprehensive genomic profiling (CGP) is an essential component of CGM, as it facilitates the identification of actionable alterations, clinical trial enrollment, and treatment selection. Following the initiation of national insurance coverage in 2019, Japan has established a nationwide CGM network. However, clinical implementation remains limited by institutional restrictions, such as delayed testing and insufficient access to matched therapies. Recent evidence from CGP-guided therapies and expanding tumor-agnostic approvals, including those for trastuzumab deruxtecan for human epidermal growth factor receptor 2 (HER2)- positive solid tumors and alectinib for anaplastic lymphoma kinase (ALK) fusion-positive solid tumors, underscores the growing therapeutic relevance of molecular profiling and is expected to further accelerate precision oncology. This review summarizes recent advances in CGM that enable treatment selection based on molecular alterations beyond conventional tumor type-based approaches and discusses future directions considering the current healthcare system and challenges in Japan.
No takes yet. Share an insight, caveat, or question.
Sasaki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: